Menu Search
Equities

Genetic Technologies Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DU8:STU

Genetic Technologies Ltd

Actions
  • Price (EUR)0.029
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta0.0531
Data delayed at least 15 minutes, as of Oct 17 2024.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its EasyDNA brand. It offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company's segments include EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType/Corporate: relates to geneType branded test sales and expense, includes corporate charges.

  • Revenue in AUD (TTM)3.71m
  • Net income in AUD-8.65m
  • Incorporated1987
  • Employees58.00
  • Location
    Genetic Technologies LtdSuite 7, Level 1, 321 Chapel StreetMELBOURNE 3181AustraliaAUS
  • Phone+61 39415-1135
  • Fax+61 38412-7040
  • Websitehttps://genetype.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GTG:ASX since
announced		Transaction
value
Ellerfield Wealth Pty LtdAnnounced06 Jun 202506 Jun 2025Announced-2.50%4.55m
Walker Capital Private Wealth Pty LtdAnnounced06 Jun 202506 Jun 2025Announced-2.50%546.00k
Data delayed at least 20 minutes, as of Oct 16 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.